All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: A matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

Annals of Oncology

Volumn 15, Issue 12, 2004, Pages 1790-1797

  Mounier, Nicolas ^a   Gisselbrecht, C ^a   Briere J ^a,b   Haioun, C ^a,b   Feugier, P ^a   Offner, F ^a,b   Recher, C ^a   Stamatoullas, A ^a   Morschhauser, F ^a   Macro, M ^a   Thieblemont, C ^a   Sonet, A ^a   Fabiani, B ^a   Reyes, F ^a   Albin, N ^b   Allard, C ^b   Aoudjane, M ^b   Assouline, D ^b   Attal, M ^b   Audhuy, B ^b   Azagury, M ^b   Barats, J C ^b   Beaumont, C ^b   Baumelou, E ^b   Biron, P ^b   Blanc, M ^b   Bordessoulle, D ^b   Bouabdallah, R ^b   Bouleuc, C ^b   Bourquard, P ^b   Bourquelot, P ^b   Boue F ^b   Boulat, O ^b   Brice, P ^b   Brun, G ^b   Caillot, D ^b   Casasnovas, O ^b   Carde, P ^b   Castaigne, S ^b   Cheze S ^b   Christian, B ^b   Colin, P ^b   Collet, C ^b   Conroy, T ^b   Cosnard, T ^b   Corront, B ^b   Cure H ^b   Delmer, A ^b   Delwail, V ^b   Detourmignies, L ^b   Devidas, A ^b   Dombret, H ^b   Dor, J F ^b   Doyen, C ^b   Dreyfus, F ^b   Dront, S ^b   Dupont, G ^b   Dupriez, B ^b   Eisenmann, J C ^b   Fabbro, M ^b   Ferme C ^b   Fillet, G ^b   Flesch, M ^b   Fruchart, C ^b   Gabarre, J ^b   Herbrecht, R ^b   Hermine, O ^b   Huyn, A ^b   Huguet, F ^b   Janvier, M ^b   Jourdan, E ^b   Karsenti, J M ^b   Kerneis, Y ^b   Kohser, F ^b   Leblond, V ^b   Lederlin, P ^b   Lefort, S ^b   Lenain, P ^b   Lepeu, G ^b   Lepretre, S ^b   Levaltier, X ^b   Le Rol, A ^b   Marit, G ^b   Martin, C ^b   Mayer, F ^b   Nouvel, C ^b   Morel, P ^b   Moriceau, M ^b   Munck, J N ^b   Nedellee, G ^b   Pavlovitch, J M ^b   Plantier, I ^b   Peaud P Y ^b   Peny, A M ^b   Pico, J ^b   Platini, C ^b   Pollet, J P ^b   more..

^a SAINT LOUIS HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Aggressive lymphoma; Autotransplantation; B phenotype; Prognostic factors; Survival analysis; T phenotype

Indexed keywords

BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINDESINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

EID: 19944425806     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh471     Document Type: Article

References (30)

1. Shipp MA, Yeap BY, Harrington DP et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 1990; 8: 84-93.
2. Coiffier B, Gisselbrecht C, Herbrecht R et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989; 7: 1018-1026.
3. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596-602.
4. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
5. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
6. Shipp MA, Abeloff MD, Antman KH et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol 1999; 17: 423-429.
7. Haioun C, Lepage E, Gisselbrecht C et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1131-1137.
8. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025-3030.
9. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma [see comments]. N Engl J Med 1997; 336: 1290-1297.
10. Santini G, Salvagno L, Leoni P et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16: 2796-2802.
11. Milpied JN, Deconinck E, Colombat P et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287-1295.
12. Gisselbrecht C, Lepage E, Molina T et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472-2479.
13. Kaiser U, Uebelacker I, Abel U et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol 2002; 20: 4413-4419.
14. Martelli M, Gherlinzoni F, De Renzo A et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol 2003; 21: 1255-1262.
15. Verdonck LF, van Putten WL, Hagenbeek A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045-1051.
16. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
17. Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003; 348: 1777-1785.
18. Rodriguez J, Munsell M, Yazji S et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001; 19: 3766-3770.
19. Mounier N, Simon D, Haioun C et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2002; 20: 1426-1427.
20. Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92: 76-82.
21. Armitage JO, Vose JM, Linder J et al. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma. J Clin Oncol 1989; 7: 1783-1790.
22. Gisselbrecht C, Mounier N, Haioun C et al. Impact in clinical practice of timing of up-front autotransplantation (ASCT) in aggressive lymphomas patients with poor prognosis. Ann Oncol 2002; 13 (Suppl 2): 76 (Abstr 253).
23. Harris NL, Jaffe ES, Diebold J et al. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
24. Cheson BD, Horning SJ, Coiffier B et al. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. J Clin Oncol 1999; 17: 1244.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
26. Cox DR. Regression model and life tables. J R Stat Soc B 1972; 34: 187-220.
27. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 2001; 93: 22-30.
28. Tilly H, Mounier N, Lederlin P et al. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. J Clin Oncol 2000; 18: 1309-1315.
29. Tilly H, Lepage E, Coiffier B et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284-4289.
30. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.